Oncology Pharmacy Specialty Review Course, Workbook Chapters (No Recert Credit) (L269049)

ACPE #: 0204-9999-26-910-H01-P 

Adult Acute Leukemias and Myelodysplastic Syndromes 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic neoplasms.
• Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic neoplasms.  
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic neoplasms in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate. 
• Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic neoplasms in an adult based on genomic test results.   

Chronic Leukemias 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration relevant molecular biology testing, genomic information, efficacy and safety outcomes from clinical trials, and current treatment guidelines for patients with chronic leukemia. 
• Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies. 
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.  

Pharmacogenomics in Oncology 

• Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques. 
• Apply the results from germline and somatic genetic testing into therapeutic recommendations based on prognostic, predictive and patient characteristics.  
• Recognize the place in therapeutic decision making for companion diagnostic testing.  

ACPE #: 0204-9999-26-911-H01-P 

Research Design, Statistics, and Evaluating Oncology Literature 

• Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population. 
• Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials). 
• Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research. 
• Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.   

Gynecologic Malignancies 

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.  
• Discuss short- and long-term goals including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver. 
• Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention and screening).  

Upper Gastrointestinal and Hepatocellular Carcinomas 

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.  
• Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies. 
• Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.  

ACPE #: 0204-9999-26-912-H01-P 

Breast Cancer 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer. 
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver. 
• Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results 
• Identify appropriate diagnostic and prognostic tests related to breast cancer. 
• Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).   

Multiple Myeloma 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma. 
• Evaluate oncology pharmacy services for compliance with established REMS regulations and standards. 
• Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression.  

ACPE #: 0204-9999-26-913-H01-P 

Oncology Practice Management 

• Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for handling, administration, and disposal of hazardous drugs. 
• Select quality-improvement activities that enhance the safety and effectiveness of the medication-use processes in oncology patient care. 
• Explain methods to optimize medication inventory management for oncology patients. 
• Evaluate policies and procedures related to conducting research involving of investigational drugs, including drug management in patients with cancer.  

Lymphomas 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma. 
• Assess the prognostic impact of relevant cancer-related molecular biology testing. 
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.  

Melanoma and Non-Melanoma Skin Cancers 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer. 
• Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver. 
• Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).  
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.  

ACPE #: 0204-9999-26-914-H01-P 

Lung Cancer 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer. 
• Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).  
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer. 
• Develop an appropriate plan for preventing, monitoring, and managing adverse reactions associated with tyrosine kinase inhibitors and mTOR inhibitors.  

Head, Neck, Adult Central Nervous System, and Thyroid Cancers 

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS), or thyroid cancers. 
• Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, screening). 
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia.  

Bladder, Renal, and Testicular Cancers 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal cell, or testicular carcinomas. 
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal cell, or testicular carcinomas and his or her caregiver. 
• Develop an appropriate plan for preventing, monitoring, and managing QT interval prolongation associated with antineoplastics and oncology supportive care agents.    

ACPE #: 0204-9999-26-915-H01-P 

 Hematopoietic Cell Transplantation 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic cell transplantation (HCT). 
• Apply appropriate strategies to prevent and treat toxicity from chemotherapy agents employed in HCT conditioning regimens. 
• Create a plan for prevention and management of acute and chronic graft-versus-host disease (GVHD) using appropriate systemic and ancillary therapies.   
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with the patient undergoing HCT and his or her caregiver.  

Prostate Cancer 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer. 
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver. 
• Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).   

Lower Gastrointestinal and Pancreatic Cancers 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers. 
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver. 
• Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).  
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.  

ACPE #: 0204-9999-26-916-H01-P 

Pediatric Malignancies and Supportive Care 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer. 
• Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer. 
• Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship. 
• Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.  

Cancer-related Infectious Diseases 

• Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases. 
• Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.  

Adult Sarcomas 

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma. 
• Adjust treatment and monitoring plans as needed based on tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate). 
• Develop an appropriate plan for preventing, monitoring and managing common problems associated with the treatment of adult patients with cancer including neurotoxicity from ifosfamide and hemorrhagic cystitis. 

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.  

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.  

The following persons in control of this activity’s content have relevant financial relationships:  

• Hiba Ahmad: Delphi Panel Member, Astellas
• Miranda Benfield: Advisory Board, Versatem 
• Courtney C. Cavilieri: Advisory Board, Bristol Myers Squibb 
• Kevin Chen: Research Grant, Lilly; Consultant, Amgen; Consultant, Bristol Myers Squibb; Consultant, Daiichi Sankyo; Consultant, Johnson & Johnson; Consultant, Merck 
• Shahrier Hossain: Advisory Board, Sanofi 
• Lauren Ice: Consultant, Janssen Biotech 
• Megan May: Speaker’s Bureau, Consultant, Amgen; Speaker’s Bureau, AstraZenca; Speaker’s Bureau, Genmab; Speaker’s Bureau, Abbvie; Speaker’s Bureau, Pharmacosmos 
• Colleen McCabe: Advisory Board, Immunocore 
• Donald Moore: Advisory Board, Incyte; Advisory Board, Genentech; Advisory Board, GSK, Eli Lilly; Consultant, Genmab 
• Anthony J. Perissinotti: Consultant, Servier; Consultant, Abbvie; Consultant, Amgen; Advisor, Syndax 
• Kristin Wheatley: Advisory Board, Jazz Pharmaceutical; Advisory Board, Sobi; Advisory Board, Amgen, Inc. 
• All other planners, presenters, reviewers, ASHP staff, and others with an opportunity to control content report no financial relationships relevant to this activity.  

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.